PROKIDNEY CORP. cotiza a 1.67 USD y tiene una capitalización bursátil de $343M. En los últimos 12 meses ha facturado $818000 con un margen de flujo de caja libre del -15152.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanc…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.15 | $-0.14 | $-0.14 |
| Estimado | — | $-0.14 | $-0.14 | $-0.15 |
| Sorpresa | — | -7.1% | +0.0% | +6.7% |
| Métrica | PROK | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -18477.8% | -38.6% | -18439.2% |
| Net Margin | -7725.2% | -33.6% | -7691.6% |
| FCF Margin | -15152.6% | -13.9% | -15138.8% |
| ROE | — | -40.4% | — |
| ROA | -20.6% | -32.0% | +11.4% |
| Current Ratio | 9.13 | 2.84 | +6.29 |
| Debt / Equity | — | 0.28 | — |